Macular dystrophy

Nanoscope Therapeutics Announces Completion of Enrollment in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease

Retrieved on: 
Tuesday, September 13, 2022

DALLAS, Sept. 13, 2022 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced full enrollment of its Phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for Stargardt disease. Six-month data from the Phase 2 STARLIGHT trial are expected in H1 2023.

Key Points: 
  • "We are excited by the therapeutic potential of MCO-010, supported by robust data from previous preclinical and clinical studies," said Sulagna Bhattacharya, CEO of Nanoscope.
  • The Phase 2 STARLIGHT open-label trial ( NCT05417126 ) enrolled six subjects with advanced vision loss due to a clinical or genetic diagnosis of Stargardt disease.
  • & Nancy J. Greene Chair and Professor of Ophthalmology at the University of Miami and principal investigator in the Phase 2 STARLIGHT trial.
  • The company has also initiated a Phase 2 trial of MCO-010 therapy in Stargardt patients ( NCT05417126 ).

Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022

Retrieved on: 
Thursday, May 5, 2022

This Phase 1b/2 study examined the safety and tolerability of LBS-008, a retinol binding protein 4 (RPB4) antagonist, in adolescent STGD1 subjects.

Key Points: 
  • This Phase 1b/2 study examined the safety and tolerability of LBS-008, a retinol binding protein 4 (RPB4) antagonist, in adolescent STGD1 subjects.
  • Preclinical studies have shown that RBP4 inhibition slows disease progression and prevents retinal degeneration in a STGD1 animal model.
  • Childhood-onset STGD1 is characterized by accumulation of bisretinoids which cause progressive retinal atrophy leading to rapid visual loss.
  • The Phase 1b/2 study is a multicenter, single arm, open-label study followed by a 2-year extension to evaluate safety, tolerability and efficacy of LBS-008.

Foundation Fighting Blindness and Nixon Visions Foundation Collaborate to Combat Inherited Retinal Diseases

Retrieved on: 
Wednesday, December 15, 2021

COLUMBIA, Md., Dec. 15, 2021 /PRNewswire/ --The Foundation Fighting Blindness , the world's leading organization committed to finding treatments and cures for blinding retinal diseases, has announced the launch of the Nixon Visions Foundation Inherited Macular Dystrophy Program formed through a collaboration with the Nixon Visions Foundation.

Key Points: 
  • COLUMBIA, Md., Dec. 15, 2021 /PRNewswire/ --The Foundation Fighting Blindness , the world's leading organization committed to finding treatments and cures for blinding retinal diseases, has announced the launch of the Nixon Visions Foundation Inherited Macular Dystrophy Program formed through a collaboration with the Nixon Visions Foundation.
  • In addition, the Foundation Fighting Blindness will partner with the University of California San Diego to conduct a workshop under the title of "Nixon Visions Foundation Inherited Macular Dystrophy Comprehensive International Workshop with Special Focus on PRPH2."
  • Their support of the Foundation's mission to find treatments and cures for inherited retinal diseases is inspiring," said Benjamin Yerxa, PhD, chief executive officer, Foundation Fighting Blindness.
  • In coordination with the Nixon Visions Foundation, the Foundation Fighting Blindness will build awareness in the inherited retinal disease community about PRPH2 (also known as RDS, which encodes the peripherin-2 protein) mutations and its effect on blindness.

US Wet Age-Related Macular Degeneration Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

The "US Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Wet Age-Related Macular Degeneration Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Wet Age-Related Macular Degeneration pipeline products, Wet Age-Related Macular Degeneration epidemiology, Wet Age-Related Macular Degeneration market valuations and forecast, Wet Age-Related Macular Degeneration drugs sales and competitive landscape in the US.
  • Wet Age-Related Macular Degeneration pipeline: Find out the products in clinical trials for the treatment of Wet Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Wet Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Wet Age-Related Macular Degeneration in the US
    Wet Age-Related Macular Degeneration drugs: Identify key products marketed and prescribed for Wet Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Wet Age-Related Macular Degeneration drugs sales: Find out the sales revenues of Wet Age-Related Macular Degeneration drugs in the US
    Wet Age-Related Macular Degeneration market valuations: Find out the market size for Wet Age-Related Macular Degeneration drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Wet Age-Related Macular Degeneration drugs market share: Find out the market shares for key Wet Age-Related Macular Degeneration drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Wet Age-Related Macular Degeneration products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005713/en/

US Dry Age-Related Macular Degeneration Market and Competitive Landscape Report 2021: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021

US Dry Age-Related Macular Degeneration Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Dry Age-Related Macular Degeneration pipeline products, Dry Age-Related Macular Degeneration epidemiology, Dry Age-Related Macular Degeneration market valuations and forecast, Dry Age-Related Macular Degeneration drugs sales and competitive landscape in the US.

Key Points: 
  • US Dry Age-Related Macular Degeneration Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Dry Age-Related Macular Degeneration pipeline products, Dry Age-Related Macular Degeneration epidemiology, Dry Age-Related Macular Degeneration market valuations and forecast, Dry Age-Related Macular Degeneration drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Dry Age-Related Macular Degeneration treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Dry Age-Related Macular Degeneration pipeline: Find out the products in clinical trials for the treatment of Dry Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Dry Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Dry Age-Related Macular Degeneration in the US
    Dry Age-Related Macular Degeneration drugs: Identify key products marketed and prescribed for Dry Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Dry Age-Related Macular Degeneration drugs sales: Find out the sales revenues of Dry Age-Related Macular Degeneration drugs in the US
    Dry Age-Related Macular Degeneration market valuations: Find out the market size for Dry Age-Related Macular Degeneration drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Dry Age-Related Macular Degeneration drugs market share: Find out the market shares for key Dry Age-Related Macular Degeneration drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Dry Age-Related Macular Degeneration products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005705/en/

Europe Age-Related Macular Degeneration Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 30, 2020

The "Europe Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Age-Related Macular Degeneration Market and Competitive Landscape - 2020, provides comprehensive insights into the Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research covers the following:
    Age-Related Macular Degeneration treatment options, Age-Related Macular Degeneration late stage clinical trials pipeline, Age-Related Macular Degeneration prevalence by countries, Age-Related Macular Degeneration market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries.
  • Age-Related Macular Degeneration pipeline: Find out drugs in clinical trials for the treatment of Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Age-Related Macular Degeneration drugs: Identify key drugs marketed and prescribed for Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Age-Related Macular Degeneration drugs sales: Find out the sales value for Age-Related Macular Degeneration drugs by countries
    Age-Related Macular Degeneration market valuations: Find out the market size for Age-Related Macular Degeneration drugs in 2019 by countries.

Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 25, 2020

The "Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2020, provides comprehensive insights into the Dry Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Dry Age-Related Macular Degeneration market size and drug sales.
  • Dry Age-Related Macular Degeneration pipeline: Find out drugs in clinical trials for the treatment of Dry Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Dry Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Dry Age-Related Macular Degeneration by countries
    Dry Age-Related Macular Degeneration drugs: Identify key drugs marketed and prescribed for Dry Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Dry Age-Related Macular Degeneration drugs sales: Find out the sales value for Dry Age-Related Macular Degeneration drugs by countries
    Dry Age-Related Macular Degeneration market valuations: Find out the market size for Dry Age-Related Macular Degeneration drugs in 2019 by countries.

Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, & Market Shares - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 22, 2020

The "Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2020, provides comprehensive insights into the Wet Age-Related Macular Degeneration pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Wet Age-Related Macular Degeneration market size and drug sales.
  • Wet Age-Related Macular Degeneration pipeline: Find out drugs in clinical trials for the treatment of Wet Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Wet Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Wet Age-Related Macular Degeneration by countries
    Wet Age-Related Macular Degeneration drugs: Identify key drugs marketed and prescribed for Wet Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Wet Age-Related Macular Degeneration drugs sales: Find out the sales value for Wet Age-Related Macular Degeneration drugs by countries
    Wet Age-Related Macular Degeneration market valuations: Find out the market size for Wet Age-Related Macular Degeneration drugs in 2019 by countries.

North America & Europe Age-related Macular Degeneration Therapeutics Market to Surpass US$ 15,122.8 Million by 2027, Says Coherent Market Insights (CMI)

Retrieved on: 
Tuesday, September 15, 2020

Key Trends and Analysis of the North America & Europe Age-related Macular Degeneration Therapeutics Market:

Key Points: 
  • Key Trends and Analysis of the North America & Europe Age-related Macular Degeneration Therapeutics Market:
    Key trends in the market are the increasing prevalence of age-related macular degeneration , the increasing number of approvals and launches of therapeutics for treatment of age-related macular degeneration, and strategic acquisitions, partnerships, and agreements by key players.
  • According to the American Academy of Ophthalmology 2020, the prevalence of age-related macular degeneration in the U.S. is roughly 8590% dry age-related macular degeneration and 1015% wet age-related macular degeneration.
  • The North America & Europe age-related macular degeneration therapeutics market is expected to exhibit a CAGR of 10.2% during the forecast period owing to launches of age-related macular degeneration therapeutics by market players.
  • Key players operating in the North America & Europe age-related macular degeneration therapeutics market are Novartis AG, Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Pfizer, Inc., and Valeant Pharmaceuticals International, Inc.
    North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type:
    North America & Europe Age-related Macular Degeneration Therapeutics Market, By Drug Type:

Global Dry Age-Related Macular Degeneration Market and Competitive Landscape 2014-2023: Pipeline, Epidemiology, Market Valuations, Product Sales, Market Forecast, Product Forecasts, and Market Shares

Retrieved on: 
Friday, October 26, 2018

The "Global Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Dry Age-Related Macular Degeneration Market and Competitive Landscape - 2018, provides comprehensive insights into Dry Age-Related Macular Degeneration pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • This study accurately estimates and forecast Dry Age-Related Macular Degeneration market size and drug sales.
  • The research is classified into following sections - Dry Age-Related Macular Degeneration overview with definitions, symptoms, etiology, diagnosis, treatment options; Dry Age-Related Macular Degeneration pipeline insights covering late stage clinical trials pipeline; Dry Age-Related Macular Degeneration prevalence trends by countries; Dry Age-Related Macular Degeneration market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.